Elusys Therapeutics and Lonza sign manufacturing agreement

Published: 26-Jun-2009

US-based Elusys Therapeutics and Lonza Sales in Switzerland have signed a production contract for Anthim, a therapeutic monoclonal antibody in late stage development for the treatment of anthrax infection.


US-based Elusys Therapeutics and Lonza Sales in Switzerland have signed a production contract for Anthim, a therapeutic monoclonal antibody in late stage development for the treatment of anthrax infection.

Under this agreement, Lonza will provide process development services and manufacturing using its GS Gene Expression System.

"Elusys has developed a very promising antibody therapeutic and we are proud to be able to support the further development of Anthim towards its commercial use," said Dr Stephan Kutzer, head of Lonza Biopharmaceuticals.

Anthim is a high-affinity, humanised and deimmunised monoclonal antibody that targets the protective antigen of B. anthracis and neutralises the lethal effects of anthrax toxins. It is being developed for prevention and treatment of inhalation anthrax. It has been granted Fast Track status and Orphan Drug Designation by the FDA.

Elusys has been awarded US$34m from the National Institutes of Health and the Department of Defense for development of Anthim.

Relevant companies

You may also like